問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

諶鴻遠
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

1Cases

2019-06-01 - 2022-12-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
  • Condition/Disease

    Differentiated Thyroid Cancer

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet

Participate Sites
4Sites

Recruiting4Sites